A combination of vilanterol and fluticasone is included in Breo Ellipta inhalation powder. Fluticasone is a kind of steroid that arrests the release of inflammation-causing substances in the body. Vilanterol is a kind of bronchodilator which works to improve breathing by relaxing muscles in the airways.
How Effective is Breo Ellipta Inhalation Powder in Reducing Inflammation?
Breo Ellipta inhalation powder is effective in reducing the inflammation caused by COPD or Asthma. Breo Ellipta inhalation powder is used by adults suffering from COPD (chronic obstructive pulmonary disease) or asthma. Breo Ellipta improves the symptoms and prevents asthma attacks or bronchospasm.
People suffering from COPD have to take Breo Ellipta inhalation powder for a long term. People suffering from asthma take this medicine only for short term until the symptoms are controlled.
- If you are allergic to milk proteins, vilanterol or fluticasone, you Must Not use Breo Ellipta. One must understand that Breo Ellipta is not a rescue medicine. It will not work fast and immediately for treating bronchospasm or asthma attack.
- Vilanterol might increase the risk of death in those suffering from asthma but what its risk to the people with COPD is still unknown. Ensure that you speak with your doctor about your individual benefits and risks of using this medicine.
- Fluticasone has the ability to weaken the immune system which might result in any new infection or worsen any infection that you might already have. Ensure that you tell your doctor about any infection or illness that you have had in past weeks.
To make sure this medicine is safe for you, tell your doctor if you’re suffering from:
- A weak immune system
- Diabetes or thyroid disorder
- High blood pressure, heart disease or liver disease
- Cataract or glaucoma
- A family history of osteoporosis
- Any infection including herpes infection in eyes or tuberculosis.
Side Effects of Breo Ellipta Inhalation Powder in Reducing Inflammation
Patients need to take the bad with the good when it comes to breo ellipta inhalation powder for reducing inflammation. Become aware of the common side effects of Breo Ellipta:
- Sore throat
- Stuffy or runny nose
- Signs of allergic reactions to Breo Ellipta
- Swelling of throat, tongue, lips and face
- Difficulty in breathing
Immediately get emergency medical help if you see any signs of allergic reactions. If you are suffering from any of the following, see your doctor:
- Wheezing or Choking
- Breathing problems after using this medicine
- Nervousness or tremors
- Shortness of breath
- Chest Pain
- Feeling tired or weak
- Vomiting and nausea
- Feeling like you may pass out
- Seeing halos around eyes
- Eye pain, tunnel vision or blurred vision
- Cough with green or yellow mucus
- Chills or fever
- Pain while swallowing food or water
- White patches or sores in throat or mouth
- Low potassium causing constipation, leg cramps, extreme thirst, limp feeling, muscle weakness, tingling, numbness, increased urination or fluttering in chest.
- High blood sugar resulting in weight loss, blurred vision, dry skin, drowsiness, breath odor, dry mouth, hunger, increased urination and increased thirst.
What is the Recommended Dosage of Breo Ellipta Inhalation Powder?
Adult Dose for Those Suffering From Chronic Obstructive Pulmonary Disease or COPD
Vilanterol 25 mcg – Fluticasone 100 mcg; take 1 breo ellipta inhalation once a day (Orally)
Maximum dose to be taken: 1 inhalation in 24 hours
- Long-term maintenance treatment
- Airflow obstruction in patients suffering from COPD, emphysema or chronic bronchitis
- Reduce exacerbations in patients suffering from COPD.
Adult Dose for Those Suffering from Asthma
Initial dose: Vilanterol 25 mcg – Fluticasone 200 mcg or Vilanterol 25 mcg – Fluticasone 100 mcg: 1 breo ellipta inhalation must be taken once a say, orally. Maximum dose to be taken is 1 inhalation of Vilanterol 25 mcg – Fluticasone 200 mcg in 24 hours
- Patients suffering from long-term asthma medication like inhaled corticosteroid which is inadequately controlled.
- When the disease severity warrants initiation of the treatment with both a long-acting beta-adrenoceptor agonist and an inhaled corticosteroid.